The effects of antipsychotic switching on diabetes in chronic schizophrenia

BackgroundPeople with severe mental illness have a 20-year life-expectancy shortfall. The majority of antipsychotic medications are associated with obesity and heightened diabetes risk. People with severe mental illness less frequently achieve benchmarked diabetes care, often attributed to poor adherence, lower clinical attendance and documented medical biases in treatment. This case is presented to highlight the profound effect medication change can have on diabetes control. Case reportA 56-year-old man with a 42-year history of schizophrenia had required clozapine treatment for the preceding 14years. Type2 diabetes and obesity occurred within 4years of clozapine instigation. Glycaemic control had been continuously poor, despite frequent contact with diabetes services and multiple medications, including insulin at a dose exceeding 200IU daily. Request for consideration of antipsychotic review and close interaction with the psychiatry team was initiated at the diabetes outpatient clinic. A gradual medication switch from clozapine to aripiprazole was associated with a reduction in HbA(1c) from 80 to 50mmol/mol (9.5 to 6.7%) over 4months, associated with a weight loss of 10kg. Over the ensuing 2years, the improvement in HbA(1c) has endured, with total weight loss of 13kg and halving of insulin requirements. ConclusionThis case illustrates the benefits of engagement between endocrinologists and psychiatrists to achieve the shared goal of improved physical health in severe mental illness. Greater interdisciplinary collaboration will help bridge the life-expectancy gap in severe mental illness and may assist in preventing disabling diabetes complications in this vulnerable patient group.